Dr. Reddy’s Laboratories Limited (RDY) Q3 2026 Earnings Call January 21, 2026 9:00 AM EST

Company Participants

Aishwarya Sitharam - Lead of Investor Relations Mannam Venkatanarasimham - CFO & Member of the Management Council Erez Israeli - CEO & Member of the Management Council

Conference Call Participants

Neha Manpuria - BofA Securities, Research Division Damayanti Kerai - HSBC Global Investment Research Bino Pathiparampil - Elara Securities (India) Private Limited, Research Division Abdulkader Puranwala - ICICI Securities Limited, Research Division Kunal Dhamesha - Macquarie Research Madhav Marda - Fidelity Investments Shyam Srinivasan - Goldman Sachs Group, Inc., Research Division Tushar Manudhane - Motilal Oswal Securities Limited, Research Division Vivek Agrawal - Citigroup Inc., Research Division Kunal Lakhan - CLSA Limited, Research Division Shashank Krishnakumar - Emkay Global Financial Services Ltd., Research Division Surya Patra - PhillipCapital (India) Pvt. Ltd., Research Division Foram Parekh - BOB Capital Markets Limited, Research Division

Presentation

Aishwarya Sitharam Lead of Investor Relations

Good day, everyone, and welcome to the Quarter 3 FY ’26 Earnings Call of Dr. Reddy’s Laboratories Limited. We appreciate your continued interest in our company. I’m Aishwarya Sitharam, Head of Investor Relations at Dr. Reddy’s.

Joining us today are members of the leadership team. Mr. Erez Israeli, our Chief Executive Officer; and Mr. M.V. Narasimham, MVN, our Chief Financial Officer.

Our quarterly financial results have been published earlier today and are available on our website for your reference. We will start today’s call with MVN providing an overview of our financial performance for the quarter. Following that, Erez will share his insights on key business highlights as well as the company’s strategic outlook. We will then open the floor for questions. All commentary and analysis during this call are based on our IFRS consolidated financial statements.

Please note that certain non-GAAP financial measures may also be discussed. Reconciliations to the corresponding GAAP measures are included in our